An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
X4 Pharmaceuticals announced the issuance of inducement awards to new employees under the 2019 Inducement Plan, consisting of options to purchase 605,349 shares of X4's common stock. The options have a ten-year term, with an exercise price of $1.12 per share, and will vest over a four-year period, subject to continued employment.
X4 Pharmaceuticals ha annunciato l'emissione di premi di incentivazione per i nuovi dipendenti nell'ambito del Piano di Induzione 2019, consistente in opzioni per l'acquisto di 605.349 azioni del capitale ordinario di X4. Le opzioni hanno una durata di dieci anni, con un prezzo di esercizio di 1,12 dollari per azione, e matureranno in un periodo di quattro anni, a condizione che continui l'impiego.
X4 Pharmaceuticals anunció la emisión de premios de incentivo a nuevos empleados bajo el Plan de Inducción 2019, que consisten en opciones para comprar 605,349 acciones del capital común de X4. Las opciones tienen un plazo de diez años, con un precio de ejercicio de $1.12 por acción, y se adquirirán durante un período de cuatro años, sujeto a la continuidad del empleo.
X4 Pharmaceuticals는 2019년 유인 계획에 따라 새로운 직원들에게 발행된 유인 상을 발표했습니다. 이 계획은 X4의 보통 주식 605,349주를 구매할 수 있는 옵션으로 구성되어 있습니다. 이 옵션은 10년의 기간을 가지며, 주당 $1.12의 행사 가격으로 설정되어 있고, 4년 동안의 기간에 걸쳐 근속 조건에 따라 권리가 부여됩니다.
X4 Pharmaceuticals a annoncé l'émission de primes d'incitation pour les nouveaux employés dans le cadre du Plan d'Incitation 2019, comprenant des options d'achat de 605,349 actions ordinaires de X4. Les options ont une durée de dix ans, avec un prix d'exercice de 1,12 $ par action, et seront acquises sur une période de quatre ans, sous réserve de la poursuite de l'emploi.
X4 Pharmaceuticals gab die Ausgabe von Anreizpreisen für neue Mitarbeiter gemäß dem Anreizplan 2019 bekannt, bestehend aus Optionen zum Erwerb von 605.349 Aktien der Stammaktien von X4. Die Optionen haben eine Laufzeit von zehn Jahren, mit einem Ausübungspreis von 1,12 $ pro Aktie, und werden sich über einen Zeitraum von vier Jahren vestieren, vorausgesetzt die Beschäftigung wird fortgesetzt.
Positive
None.
Negative
None.
BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on April 30, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 605,349 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
The options have a ten-year term and an exercise price of $1.12 per share, which is equal to the closing price of X4’s common stock on April 30, 2024. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee’s continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.
About X4 Pharmaceuticals X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI™ (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
How many shares of X4's common stock were granted as inducement awards?
605,349 shares of X4's common stock were granted as inducement awards.
What is the exercise price per share for the options?
The exercise price per share for the options is $1.12.
How long is the term for the options?
The options have a ten-year term.
How will the options vest?
The options will vest over a four-year period, with 25% vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to continued employment.
x4 pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and reverse immune suppression, which is fundamental to treating cancer and certain rare, genetic primary immunodeficiency diseases. our oral, small molecule drug candidates inhibit the binding of chemokine cxcl12 to c-x-c receptor type 4 (cxcr4), a receptor-ligand pair that plays an essential role in normal immune surveillance. we are committed to advancing the fields of cancer immunotherapy and genetic immune disorders through innovation and investment in our proprietary clinical and preclinical pipeline. x4’s most advanced product candidate, x4p-001-rd, is in a phase 2/3 study in patients with whim syndrome, a rare genetic, primary immunodeficiency disease. x4p-001-io is currently under investigation in multiple phase 1/2 studies in refractory clear cell renal cell carcinoma (ccrcc) and melanoma. our third program, x4p-002, is in preclinical development and designed specifically for the t
